ProfileGDS5678 / 1417420_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 95% 94% 96% 94% 93% 95% 94% 95% 96% 96% 96% 97% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1908694
GSM967853U87-EV human glioblastoma xenograft - Control 28.3899495
GSM967854U87-EV human glioblastoma xenograft - Control 38.1815494
GSM967855U87-EV human glioblastoma xenograft - Control 48.9281396
GSM967856U87-EV human glioblastoma xenograft - Control 58.2772494
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.7361993
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0750895
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1395994
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.3784795
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.922396
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.9093896
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.805696
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.2705697
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.8042296